Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Company Overview

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies.

Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches.

Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.

Key Stats

• Today's Range: $16.06 to $17.39
• 50-Day Range: $14.43 to $17.51
• 52-Week Range: $8.19 to $22.50
• Volume: 1.32 million shs
• Average Volume: 1.00 million shs
• Market Capitalization: $1.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.46
• Consensus Rating: Moderate Buy

Nurix Therapeutics Stock Analysis - MarketRank™

Nurix Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 428th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Nurix Therapeutics has a consensus price target of $30.46, representing about 83.5% upside from its current price of $16.60.

Amount of Analyst Coverage

Nurix Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nurix Therapeutics are expected to grow in the coming year, from ($2.94) to ($2.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nurix Therapeutics is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nurix Therapeutics is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nurix Therapeutics has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.90% of the float of Nurix Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 14.08, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nurix Therapeutics does not currently pay a dividend.

Dividend Growth

Nurix Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.70

News Sentiment

Nurix Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Nurix Therapeutics this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $326,586.00 in company stock.

Percentage Held by Insiders

6.70% of the stock of Nurix Therapeutics is held by insiders.

Percentage Held by Institutions

Nurix Therapeutics has minimal institutional ownership at this time.

NRIX Stock Analysis - Frequently Asked Questions

How have NRIX shares performed this year?

Nurix Therapeutics' stock was trading at $18.97 at the start of the year. Since then, NRIX stock has decreased by 12.5% and is now trading at $16.60.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its quarterly earnings data on Wednesday, April, 8th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.03. The company had revenue of $6.25 million for the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative trailing twelve-month return on equity of 64.21%.

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $187 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 11,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Nurix Therapeutics' major shareholders?

Top institutional investors of Nurix Therapeutics include Pictet Asset Management Holding SA (2.64%), Sumitomo Mitsui Trust Group Inc. (1.14%), Bank of New York Mellon Corp (0.29%) and Y Intercept Hong Kong Ltd (0.05%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van and Christine Ring.
View institutional ownership trends.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

• Last Earnings: 4/08/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 7/09/2026
• Fiscal Year End: 11/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRIX
• CIK: 1549595
• Web: www.nurixtx.com
• Phone: 415-660-5320
• Fax: N/A
• Employees: 300
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Nurix Therapeutics: $30.46
• High Price Target: $36.00
• Low Price Target: $26.00
• Potential Upside/Downside: +83.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$264.46 million
• Net Margins: -411.37%
• Pretax Margin: -410.32%
• Return on Equity: -64.21%
• Return on Assets: -48.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.01
• Quick Ratio: 6.01

Sales & Book Value

• Annual Sales: $83.98 million
• Price / Sales: 20.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.29 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 103,410,000
• Free Float: 96,478,000
• Market Cap: $1.72 billion
• Optionable: Optionable
• Beta: 1.87